The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...
Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...
In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...
Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...
The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...
NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.
Pharmaceutical Technology on MSN4d
UK’s pricing watchdog rejects Alzheimer treatments for the second timeThe UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...
Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback